We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A California supplement maker is in hot water after being accused of making drug-like claims about its products and relying on improper production methods. Read More
A growing number of health insurers are asking pharmaceutical manufacturers to tie payment to how a drug performs. Some drugmakers are taking the leap into this relatively unchartered territory. Read More
The proposed transaction would consist of an exchange of Sanofi’s Merial animal health business and Boehringer’s consumer healthcare business. Read More
For the third time in four months, a federal judge has delayed drugmaker Amarin’s lawsuit against the FDA as the two sides try to negotiate a settlement. Read More
Drugmakers that have not started complying with worldwide track and trace regulations are behind the eight ball, as most companies only allow for two to three years for implementation, a supply chain expert warns. Read More
Valeant Pharmaceuticals faced renewed scrutiny Wednesday on two fronts, with a lawmaker accusing the company of obstructing a congressional investigation and investors questioning the company’s long-term viability in the face of a dismal earnings report. Read More
Legal experts say the FDA’s off-label regulation of pharmaceuticals may be on shaky ground after it agreed to settle with Pacira Pharmaceuticals this week in a case involving the pain drug Exparel. Read More